Glenmark Pharma’s innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a ‘Buy’ rating.
Asian stocks advance as Fed’s rate cut lifts mood
Asian markets followed Wall Street higher after the US Federal Reserve lowered interest rates. Fed Chair Jerome Powell indicated confidence in the US economy’s future.
December 11, 2025